The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.

A direct path to venture capital in biotech is less effective than one that includes deep operational experience. Gaining experience in research, business development, commercial, and startup C-suite roles provides the credibility and understanding to "speak eye to eye" with portfolio companies and become a much better investor.

An estimated 60% of VCs harm their portfolio companies by pushing a 'burn at all costs' mentality or pretending to know how to run the business. The best VCs are humble connectors who link founders with people who have successfully navigated similar growth stages before.

A successful early-stage strategy involves actively maximizing specific risks—product, market, and timing—to pursue transformative ideas. Conversely, risks related to capital efficiency and team quality should be minimized. This framework pushes a firm to take big, non-obvious swings instead of settling for safer, incremental bets.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

Small biotechs face a paradox: they must pursue highly innovative, risky science to differentiate themselves, as "me-too" drugs won't attract investment. The key to survival is managing this high scientific risk with strategies that provide fast, capital-efficient data for go/no-go decisions.

Santé Ventures operates on the principle that a 40-50% loss ratio is inherent to early-stage biotech investing. Attempting to reduce this failure rate is seen as a sign of not taking enough risk. The core strategy is ensuring the winners are large enough to pay for all the losers.

CEO Fred Aslan categorizes biotech ventures by their primary challenge: "biology risk" (the science is unproven) or "execution risk" (the science works, but market and operational challenges are high). He was attracted to Artiva because its NK cell therapy was an execution play on the de-risked biology of B cell depletion, focusing on access, cost, and scalability.